Starting heart drugs after a STEMI heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting a beta blocker and an SGLT2 inhibitor right after a heart attack can help preserve heart function. It is for STEMI patients who have not yet been treated with these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had a STEMI heart attack and gotten a stent within 6 hours of symptoms starting.
- You cannot be currently taking common heart or diabetes medicines like beta blockers, ACE inhibitors, ARBs, or SGLT2 inhibitors.
- You should not have severe heart failure or kidney problems (GFR below 25).
- You should not have a life-threatening illness that would make your outlook less than a year.
- If you are a woman who can get pregnant, you must use birth control or have had sterilization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This trial tests a heart medication (a cardio-selective beta-blocker) given during a heart attack to see if it reduces damage to the heart muscle. It might help people having their first heart attack who are treated quickly with angioplasty (a procedure to open blocked arteries).
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
Hear when a new Myocardial Infarct trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.